AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs from its boron chemistry platform. Its pipeline includes boron-based compounds for Chagas disease, non-tuberculous mycobacterial (NTM) lung disease, and melioidosis, along with earlier-stage programs in infectious diseases and oncology. The company does not yet have any approved products or commercial revenue, so its business is centered on advancing candidates through preclinical work, clinical trials, and regulatory review. AN2 relies heavily on third-party research, clinical, and manufacturing partners while it builds the capabilities it would need for eventual commercialization.
6.87
6.87
| % | |
|---|---|
| Clinical-stage drug candidates | 100% Boron-based compounds being advanced through preclinical and clinical development for infectious diseases and oncology. |
| Research and discovery platform | 0% The boron chemistry platform used to identify and optimize novel small-molecule therapeutics. |
| Development-stage pipeline programs | 0% Programs targeting Chagas disease, NTM lung disease, melioidosis, and other high-unmet-need indications. |
AN2 does not currently sell products, so its near-term 'customers' are primarily regulators, clinical investigators,...
FDA, other regulators, CROs, and trial sites that support development and approval of product candidates.
Physicians who would prescribe approved therapies for rare or hard-to-treat infections such as NTM lung disease and Chagas disease.
Patients who would use the company's therapies if approved, especially in niche or orphan-like indications.
Insurers and reimbursement decision-makers that would determine access and pricing for any approved product.
Specialty pharmacies, distributors, and pharmaceutical partners that could help commercialize products outside the U.S.
AN2 is headquartered in the United States and currently conducts its development activities through a U.S...
AN2's strategy is to advance its boron chemistry platform into differentiated therapies for high-unmet-need infectious...
Clinical progress is the main value driver because the company has no approved products or revenue.
The company expects continued losses and needs funding to support development through regulatory milestones.
If a product is approved, AN2 will need sales, marketing, and distribution capabilities to capture value.
AN2 is exposed to the classic risks of a clinical-stage biotech: development failure, regulatory delay, and the...
The company's value depends on advancing unapproved candidates through trials and regulatory review, and success is highly uncertain.
AN2 has no product revenue and expects to rely on external capital to fund operations and development.
The company relies on CROs and CMOs, so disruptions can delay studies, increase costs, or impair supply.
Even approved drugs may not gain sufficient physician, patient, or payor acceptance to be commercially successful.
Adverse events can delay, suspend, or terminate trials and reduce market acceptance if a product is approved.
AARD · Pharmaceutical Preparations
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
ANNX · Pharmaceutical Preparations
VERA · Pharmaceutical Preparations
CERO · Biological Products, (No Diagnostic Substances)
CNTX · Pharmaceutical Preparations
: 11/08/2026